TNM and VALSG Stage Assessments in SCLC: Diagnostic Capability Comparison among PET/MRI, PET/CT, Whole-Body MRI and Conventional Examination
Yoshiharu Ohno1,2, Masao Yui3, Kaori Yamamoto3, Daisuke Takenaka4, Takeshi Yoshikawa4, Saki Takeda5, Akiyoshi Iwase5, Yuka Oshima1, Nayu Hamabuchi1, Satomu Hanamatsu1, Yuki Obama1, Hiroyuki Nagata1, Takahiro Ueda1, Hirotaka Ikeda1, Kazuhiro Murayama2, and Hiroshi Toyama1
1Radiology, Fujita Health University School of Medicine, Toyoake, Japan, 2Joint Research Laboratory of Advanced Medical Imaging, Fujita Health University School of Medicine, Toyoake, Japan, 3Canon Medical Systems Corporation, Otawara, Japan, 4Diagnostic Radiology, Hyogo Cancer Center, Akashi, Japan, 5Radiology, Fujita Health University Hospital, Toyoake, Japan
Whole-body MRI and co-registered or integrated PET combined with MRI (PET/MRI) using 1.5 T or 3T MR systems has been suggested as equal to or more accurate than PET/CT or conventional staging or recurrence surveillance methods in thoracic oncologic patients. We hypothesize that whole-body MRI and co-registered PET/MRI for SCLC patients have equal to or superior potential for VALSG and TNM stage assessments than PET/CT and conventional staging method. The purpose of this study was to prospectively compare the capabilities for assessing VALSG and TNM stages among whole-body MRI, PET/MRI, PET/CT and conventional staging method in SCLC patients.
This abstract and the presentation materials are available to members only;
a login is required.